Stock Comparison

JAZZ vs PFE

Jazz Pharmaceuticals PLC vs Pfizer Inc

The Verdict

JAZZ takes this one.

Winner

JAZZ

Jazz Pharmaceuticals PLC

0.7

out of 10

Distressed

PFE

Pfizer Inc

0.2

out of 10

Distressed

Head-to-Head

$11.9B

Market Cap

$150.6B

-33.3

P/E Ratio

19.4

-8.3%

Profit Margin

12.4%

-8.8%

Return on Equity

8.7%

1.2

Debt-to-Equity

0.7

Moderate

Overall Risk

Moderate

0.7

DVR Score

0.2

The Deep Dive

JAZZ0.7/10

Jazz Pharmaceuticals remains a well-established biopharmaceutical company with strong execution on its neuroscience and oncology portfolio. The Q4 2025 earnings beat, 10% YoY revenue growth, and 16% YoY Xywav revenue growth demonstrate stable performance. The advancement of zanidatamab (HER2+ GEA) with breakthrough designation and potential H2 2026 approval provides a significant near-term catalys...

Full JAZZ Analysis

PFE0.2/10

Pfizer Inc. remains a mature, large-cap pharmaceutical company with no material changes since the last analysis that would indicate a path to 10x growth. The company faces ongoing headwinds from declining COVID product sales and patent cliffs. While a settlement extended Vyndamax exclusivity, this is insufficient to offset broader challenges. Upcoming Q1 2026 earnings are projected to show a ~20% ...

Full PFE Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified advisor before investing.